Ipsen Aktie [WKN: A0ESMG / ISIN: FR0010259150]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Ipsen

14.05.19		Ipsen to Host an Investor Day to Highlight Its Innovative R&D Pipeline and Provide Financial Outlook for 2022 (Businesswire)
08.05.19		KNDL 2019-KNSQ Mortgage Trust -- Moody's assigns provisional ratings to five CMBS classes of KNDL 2019-KNSQ Mortgage Trust (Moodys)
08.05.19		Moody's assigns provisional ratings to five CMBS classes of KNDL 2019-KNSQ Mortgage Trust (Moodys)
24.04.19		Ipsen Reports Strong Double-Digit Sales Growth in First Quarter 2019 and Confirms Full Year 2019 Financial Targets (Businesswire)
18.04.19		Ipsen Completes Acquisition of Clementia Pharmaceuticals (Businesswire)
27.03.19		Ipsen Publishes its 2018 Registration Document (Businesswire)
28.02.19		Ipsen to Present New Data on Enhancement of Patient Care at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference (Businesswire)
25.02.19		Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion (Reuters)
25.02.19		Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio (Businesswire)
18.01.19		Ipsen: Patients Living with Spasticity Want Long-lasting Symptom Relief (Businesswire)
17.01.19		Ipsen Presents the Results of the First in-Human Study of a Recombinant Fast-Acting Neurotoxin (rBoNT-E) at TOXINS 2019 (Businesswire)
11.01.19		Ipsen demonstrates leadership position in neurotoxin research with strong presence at TOXINS 2019 (Businesswire)
05.12.18		Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma (Businesswire)
20.11.18		Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087) (Businesswire)
15.11.18		European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the treatment of hepatocellular carcinoma in adults previously treated with sorafenib (Businesswire)
25.10.18		Ipsen Delivers Strong Sales Growth of 20.2%1 for the Third Quarter of 2018 and Confirms Full Year Guidance (Businesswire)
12.10.18		Ipsen to present new data from its oncology portfolio at the 2018 European Society for Medical Oncology (ESMO) congress (Businesswire)
21.09.18		Ipsen Receives Positive CHMP Opinion for Cabometyx® (Cabozantinib) for the Second-line Treatment of Patients with Hepatocellular Carcinoma (HCC) (Businesswire)
19.07.18		Ipsen and BioLabs to open new Innovation Center in Cambridge (U.S.) to foster development of new therapies for patients (Businesswire)
04.07.18		Ipsen Announces CELESTIAL phase 3 Pivotal Trial Results in the New England Journal of Medicine (Businesswire)
04.07.18		Ipsen announces new clinical data to be presented at ISPRM 2018 demonstrating commitment to neurotoxin research (Businesswire)
04.06.18		Ipsen initiates a share buyback program to cover its free share allocation and employee share plans (Businesswire)
30.05.18		Combined Shareholders’ Meeting of IPSEN S.A. Held on 30 May 2018 (Businesswire)
30.05.18		IPSEN: Description of the Regulatory Framework of the Share Repurchase Program Proposed by the Board of Directors to Be Approved at the Combined Shareholders’ Meeting on 30 May 2018 (14th Resolution) (Businesswire)
29.05.18		Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development Partnership (Businesswire)
29.05.18		Ipsen Announces Clinical Data to Be Presented at ASCO Demonstrating Its Commitment to Patients with Cancer (Businesswire)
22.05.18		Ipsen launches employee share ownership plan (Businesswire)
17.05.18		European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma (Businesswire)
26.04.18		Ipsen Reports Strong First Quarter 2018 Sales Growth of 23.1% at Constant Exchange Rates (Businesswire)
28.03.18		Ipsen Announces EMA Validation of Filing of a New Application for Additional Indication for Cabometyx®, for Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC) (Businesswire)
26.03.18		Ipsen Publishes Its 2017 Registration Document (Businesswire)
23.03.18		Ipsen Receives Positive CHMP Opinion for Cabometyx® (cabozantinib) for the First-Line Treatment of Adults with Intermediate- or Poor- Risk Advanced Renal Cell Carcinoma (Businesswire)
13.03.18		Ipsen appoints Ivana Magovcevic-Liebisch Ph.D., J.D. and Régis Mulot to Executive Leadership Team (Businesswire)
06.03.18		Ipsen Announces 18 Posters to Be Presented at the 15th Annual ENETS Conference (Businesswire)
21.02.18		Arix Bioscience and Ipsen Sign a Strategic Agreement to Develop and Commercialise Innovative Therapies (Businesswire)
07.02.18		Ipsen Announces Eight Oral Presentations from Its Neurosciences Portfolio at the 10th World Congress for Neurorehabilitation (WCNR) (Businesswire)
22.01.18		End-Year IPSEN Liquidity Contract Statement Entered into with NATIXIS (Businesswire)
16.01.18		Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma (Businesswire)
15.01.18		Ipsen Announces 13 Posters and 1 Oral Presentation at the 2018 ASCO Gastrointestinal Symposium (Businesswire)
12.01.18		Ipsen Appoints Richard Paulson Executive Vice-President and Chief Executive Officer of Ipsen North America (Businesswire)
12.01.18		IPSEN: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
02.01.18		Ipsen Announces It is No Longer Eligible for the PEA-PME Scheme (Businesswire)
08.12.17		IPSEN: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
06.12.17		Ipsen Announces Its Corporate Agenda for 2018 (Businesswire)

Erste Seite Zurück | ... | 2 | 3 | 4 | 5 | Weiter

Newssuche

Meistgelesene Nachrichten

Diese AI-Aktie ist Cathie Woods neuer Favorit

JPMorgan: Bitcoin-Miner setzen auf Unternehmensmodell von MicroStrategy

NEL sichert sich Steuergutschrift in Millionenhöhe - Aktie sackt ab

ATX-Papier voestalpine-Aktie: So viel Verlust hätte ein voestalpine-Investment von vor einem Jahr eingefahren

Aktien von PVA TePla und SMA Solar springen hoch, VERBIO-Aktie stürzt ab: Jefferies-Analyst passt zahlreiche Bewertungen an

D-Wave Quantum-Aktie, IonQ-Aktie und Rigetti-Aktie fallen: Aktienrutsch geht trotz Beruhigungssignalen weiter

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	15.01.2025 09:30
Kaufwert:	EUR
	Hinzufügen Speichern